BJDX

Bluejay Diagnostics, Inc. (BJDX) - Q1 2026 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2026. Bluejay Diagnostics, Inc. is a medical diagnostics company developing the "Symphony" platform, a rapid, near-patient testing system for critical care settings, specifically targeting sepsis via an IL-6 biomarker test. The company is currently in the clinical validation phase and has not yet received FDA clearance or generated product revenue. The financial statements reflect a 1-for-4 reverse stock split effective January 29, 2026.

Key Financial Metrics

Capital Structure: As of March 31, 2026, there were 1,034,715 shares of common stock outstanding. The company has no long-term debt but holds significant warrant obligations (Class F, E, C, etc.) with exercise prices ranging from $7.00 to over $200,000.

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased slightly to $1.94 million from $1.89 million. Research and Development (R&D) rose to $811,837 (from $784,800) due to product development costs, while General and Administrative (G&A) expenses increased to $1.13 million (from $1.10 million) primarily due to the recognition of 2025 bonus costs.
• Cash Flow: Net cash used in operating activities increased by approximately $404,000 year-over-year, driven by a $362,000 increase in working capital requirements.
• Financing Activity: The company raised $125,000 in Q1 2026 through a private placement of 62,500 shares to directors and the CEO. This contrasts with no financing proceeds in Q1 2025.
• Other Income: Other income decreased to $19,590 from $24,482, largely due to the cessation of related-party income from NanoHybrids following a settlement agreement.

Outlook, Risks, and Management Commentary

• Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern. Cash resources are estimated to be sufficient only through the third quarter of 2026. The company estimates a need to raise at least $20 million between Q2 2026 and the end of fiscal 2027 to fund clinical trials and FDA submission efforts.
• Regulatory Strategy: The company is conducting the SYMON-II pivotal clinical study, with patient enrollment expected to complete in summer 2026. The goal is to submit a 510(k) application to the FDA in the first half of 2027. Manufacturing of cartridges is being handled by Sanyoseiko Co. Ltd.
• Risks: Failure to secure additional financing could force the company to delay its FDA strategy, reduce R&D scope, or pursue liquidation under Chapter 7 bankruptcy. There is no assurance that clinical trials will demonstrate sufficient safety and effectiveness for regulatory clearance.
• Recent Transactions: In March 2026, the company completed a private placement with insiders. In October 2025, it raised approximately $4.5 million via a private placement involving prefunded warrants and Series F warrants.

Investor Verification Checklist

• Liquidity Runway: Verify the company's ability to raise the required $20 million before Q3 2026 to avoid insolvency.
• Clinical Trial Progress: Monitor the completion of the SYMON-II study enrollment and the subsequent data analysis timeline.
• Manufacturing Status: Confirm the successful verification of cartridge manufacturing with Sanyoseiko to ensure readiness for FDA submission.
• Dilution Risk: Assess the impact of outstanding warrants (over 1.5 million shares across various classes) on future equity dilution.
• Related Party Transactions: Review the March 2026 private placement terms where proceeds were raised from the CEO and Board members at $2.00/share.